Cell Reports (Feb 2022)
Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cells
- Fraser D. Johnson,
- John Ferrarone,
- Alvin Liu,
- Christina Brandstädter,
- Ravi Munuganti,
- Dylan A. Farnsworth,
- Daniel Lu,
- Jennifer Luu,
- Tianna Sihota,
- Sophie Jansen,
- Amy Nagelberg,
- Rocky Shi,
- Giovanni C. Forcina,
- Xu Zhang,
- Grace S.W. Cheng,
- Sandra E. Spencer Miko,
- Georgia de Rappard-Yuswack,
- Poul H. Sorensen,
- Scott J. Dixon,
- Udayan Guha,
- Katja Becker,
- Hakim Djaballah,
- Romel Somwar,
- Harold Varmus,
- Gregg B. Morin,
- William W. Lockwood
Affiliations
- Fraser D. Johnson
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada
- John Ferrarone
- Meyer Cancer Centre, Weill Cornell Medicine, New York City, NY, USA
- Alvin Liu
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada
- Christina Brandstädter
- Department of Biochemistry and Molecular Biology, Justus Liebig University Giessen, Giessen, Germany
- Ravi Munuganti
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
- Dylan A. Farnsworth
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada
- Daniel Lu
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada
- Jennifer Luu
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Tianna Sihota
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Sophie Jansen
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada
- Amy Nagelberg
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Rocky Shi
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada
- Giovanni C. Forcina
- Department of Biology, Stanford University, Stanford, CA, USA
- Xu Zhang
- Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
- Grace S.W. Cheng
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada
- Sandra E. Spencer Miko
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada
- Georgia de Rappard-Yuswack
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada
- Poul H. Sorensen
- Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
- Scott J. Dixon
- Department of Biology, Stanford University, Stanford, CA, USA
- Udayan Guha
- Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
- Katja Becker
- Department of Biochemistry and Molecular Biology, Justus Liebig University Giessen, Giessen, Germany
- Hakim Djaballah
- High Throughput Screening Core Facility, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA; Keren Therapeutics, New York City, NY, USA
- Romel Somwar
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York City, NY, USA
- Harold Varmus
- Meyer Cancer Centre, Weill Cornell Medicine, New York City, NY, USA
- Gregg B. Morin
- Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada
- William W. Lockwood
- Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Interdisciplinary Oncology Program, University of British Columbia, Vancouver, BC, Canada; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Corresponding author
- Journal volume & issue
-
Vol. 38,
no. 6
p. 110343
Abstract
Summary: Phenotype-based screening can identify small molecules that elicit a desired cellular response, but additional approaches are required to characterize their targets and mechanisms of action. Here, we show that a compound termed LCS3, which selectively impairs the growth of human lung adenocarcinoma (LUAD) cells, induces oxidative stress. To identify the target that mediates this effect, we use thermal proteome profiling (TPP) and uncover the disulfide reductases GSR and TXNRD1 as targets. We confirm through enzymatic assays that LCS3 inhibits disulfide reductase activity through a reversible, uncompetitive mechanism. Further, we demonstrate that LCS3-sensitive LUAD cells are sensitive to the synergistic inhibition of glutathione and thioredoxin pathways. Lastly, a genome-wide CRISPR knockout screen identifies NQO1 loss as a mechanism of LCS3 resistance. This work highlights the ability of TPP to uncover targets of small molecules identified by high-throughput screens and demonstrates the potential therapeutic utility of inhibiting disulfide reductases in LUAD.